Synergy of Body Composition, Exercise Oncology, and Pharmacokinetics: A Narrative Review of Personalizing Paclitaxel Treatment for Breast Cancer
Authors:
- Nele AdriaenssensNele Adriaenssens
- Stephanie C. M. WuytsSWStephanie C. M. Wuyts
- Stephane SteurbautSSStephane Steurbaut
- Pieter-Jan De SutterPSPieter-Jan De Sutter
- Amy de Haar-HollemanAHAmy de Haar-Holleman
- David BeckwéeDBDavid Beckwée
- Steven ProvynSPSteven Provyn
- Sofie Vande CasteeleSCSofie Vande Casteele
- Jinyu ZhouJZJinyu Zhou
- Katrien LanckmansKLKatrien Lanckmans
Open Access
Abstract
Background/Objectives: Paclitaxel is a type of small molecule chemotherapy widely used for breast cancer, but its clinical efficacy is often hindered by dose-limiting toxicities such as chemotherapy-induced peripheral neuropathy and neutropenia. Traditional dosing based on body surface area does not account for variations in body composition, which may influence paclitaxel metabolism, toxicity, and treatment outcomes. This review explores the interplay between body composition, physical activity, and paclitaxel pharmacokinetics, emphasizing the potential for personalized dosing strategies. Methods: A comprehensive narrative review was conducted by analyzing the literature on body composition, small molecule chemotherapy-related toxicities, pharmacokinetics, and exercise oncology. Studies examining the role of skeletal muscle mass, adipose tissue, and physical activity in modulating paclitaxel metabolism and side effects were included. Results: Evidence suggests that patients with low skeletal muscle mass are at a higher risk of paclitaxel-induced toxicities due to altered drug distribution and clearance. Sarcopenic obesity, characterized by low muscle and high-fat levels, further exacerbates these risks. Exercise, particularly resistance and aerobic training, has been shown to improve muscle mass, mitigate toxicities, and enhance chemotherapy tolerance. However, the precise mechanisms by which exercise influences paclitaxel pharmacokinetics remain underexplored. Conclusions: Personalized chemotherapy dosing, considering body composition and physical activity, may optimize paclitaxel treatment outcomes. Future research should focus on integrating exercise interventions into oncology care and refining dosing models that account for interindividual differences in drug metabolism. These advancements could improve treatment efficacy while minimizing toxicities in breast cancer patients.Keywords
All Related Versions
Funding Information
- Kom op tegen kanker (Stand up to Cancer) (13163)
- Flemish Cancer Society (13163)
This publication has 141 references indexed in Scilit:
- Changes in Weight, Body Composition, and Factors Influencing Energy Balance Among Premenopausal Breast Cancer Patients Receiving Adjuvant ChemotherapyJournal of Clinical Oncology, 2001
- The effects of exercise on the pharmacokinetics of drugs.2001
- Fatigue in Women Receiving Adjuvant Chemotherapy for Breast CancerJournal of Pain and Symptom Management, 1999
- Paclitaxel (Taxol)New England Journal of Medicine, 1995
- A nursing rehabilitation program for women with breast cancer receiving adjuvant chemotherapy.1994
- Effect of Exercise on PharmacokineticsAnnals of Medicine, 1991
- Hypersensitivity reactions from taxol.Journal of Clinical Oncology, 1990
- Effects of Aerobic Interval Training on Cancer Patients?? Functional CapacityNursing Research, 1989
- Effect of aerobic exercise on body weight and composition in patients with breast cancer on adjuvant chemotherapy.1989
- Taxol produces a predominantly sensory neuropathyNeurology, 1989